1.Dr.Tan Yue gave an oral report on"DONOR-DERIVED CD7 CAR-T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA"

2.Dr.Tang Kaiting gave an oral report on"LONG-TERM FOLLOW-UP OF SEQUENTIAL CD19-22 CAR-T-CELL THERAY IN 20 CHILDREN WITH REFRACTORY OR RELAPSED B-ALL"

3.Dr.Shi Hui gave an oral report on"GENETIC LANDSCAPES AND CURATIVE EFFECT OF CAR-T CELLS IMMUNOTHERAPY IN RELAPSE AND REFRACTORY DLBCLS"

4.Dr.Zhao Defeng made a poster display with the theme of"CD22-TAGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA"

5.Dr.An Lihong made a poster display with the theme of"THE SALVAGE TREATMENT OF HUMANIZED-CD19 CAR-T CELLS FOR RELAPSED B-ALL AFTER PRIOR MURINIZED-CD19 CAR-T CELL THERAPY"

6.Dr.Guo Yuelu made a poster display with the theme of"TUMOR CHARACTERISTICS OF DISEASE PROGRESSION AFTER BCMA-CAR-T TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY LESIONS"

7.Dr.Yang Fan made a poster display with the theme of"HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CONDITIONING INCLUDING ALLOGENEIC BISPECIFIC CAR-T CELLS TARGETING BOTH CD19 AND CD22 FOR REFRACTORY/RELAPSED B-CELL NON-HODGKIN LYMPHOMA"

8.Dr.Xue Fei made a poster display with the theme of"COMBINED TREATMENT OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS TRANSPLANTATION WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IMPROVES OUTCOMES IN MANAGEMENT OF ADVANCED RELAPSED AND REFRACTORY CENTRAL NERVOUS SYSTEM B-CELL LYMPHOMA"

9.Dr.Li Zhihui reported"ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY/RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA AFTER ALLOGENEIC CD7-CAR-T CELL THERAPY"and"DONOR-DERIVED ACTIVATED NK CELLS IN MANAGEMENT OF RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA"

10.Dr.Song Yanzhi reported"PD-1 INHIBITOR SIGNIFICANTLY INCREASES ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC REFRACTORY/RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA"

11.Dr.Zheng Peihao reported"BENDAMUSTINE IS A FAVORABLE LYMPHODEPLETING CHEMOTHERAPY REGIMEN PRIOR TO CAR-T CELLS IMMUNOTHERAPY AS FLUDARABINE"